ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1290 • 2013 ACR/ARHP Annual Meeting

    Pro-Inflammatory and Anti-Inflammatory Roles Of Interferon Regulatory Factor 5 In The Development Of Collagen-Induced Arthritis

    Yoshifumi Tada1, Syuichi Koarada1, Rie Suematsu1, Satoko Tashiro1, Natsumi Nagao1 and Akihide Ohta2, 1Rheumatology, Saga University, Saga, Japan, 2Nursing, Saga University, Saga, Japan

    Background/Purpose: Interferon regulatory factor 5 (IRF5) is a transcription factor that mediates signals activated by engagement of Toll-like receptors (TLRs). IRF5 polymorphisms are associated with…
  • Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting

    COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic

    Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
  • Abstract Number: 1292 • 2013 ACR/ARHP Annual Meeting

    The Spatial Energy Expenditure Configuration and Possible Applications In An Experimental Model Of Arthritis

    Susanne Klatt1 and Rainer H. Straub2, 1Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrine Immunology, University Hospital Regensburg, Regensburg, 93055, Germany, 2Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany

    Background/Purpose: An autoimmune response with differentiation and proliferation of immune cells and the subsequent tissue-directed inflammatory process in the symptomatic phase of the disease are…
  • Abstract Number: 1294 • 2013 ACR/ARHP Annual Meeting

    Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model

    Romina R. Riveiro-Naveira1, Jesus Loureiro1, Alberto Centeno-Cortés2, Eduardo López-Peláez2, Carlos Vaamonde-García1, M. Noa Valcárcel-Ares1, Francisco J. Blanco3 and Maria J. López-Armada1, 1Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, 2Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, 3Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain

    Background/Purpose: Inflammatory cells like macrophages, lymphocytes and neutrophils in hyperplasic synovial tissue have been identified as key players in the onset and development of rheumatoid…
  • Abstract Number: 1295 • 2013 ACR/ARHP Annual Meeting

    Mechanisms For Fostamatinib-Induced Blood Pressure Elevation

    Matthew Skinner1, Karen Philp1, David Lengel2, Lucy Coverley1, Eva Lamm Bergstroem3, Philip Glaves1, Helen Musgrove1, Helen Prior1, Martin Braddock4, Russell Huby1, Jon O Curwen1, Paul Duffy1 and Alex Harmer1, 1AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 2AstraZeneca R&D Waltham, Waltham, MA, 3AstraZeneca R&D Mölndal, Mölndal, Sweden, 4AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom

    Background/Purpose: Fostamatinib is a kinase inhibitor with activity at spleen tyrosine kinase. In clinical studies in patients with rheumatoid arthritis, fostamatinib treatment was associated with…
  • Abstract Number: 1255 • 2013 ACR/ARHP Annual Meeting

    Ovarian Dysfunction In Adult Childhood-Onset Systemic Lupus Erythematosus Patients: A Possible Role Of Methotrexate?

    Daniel B. Araujo1, Lucas Yamakami2, Eloisa Bonfá3, Vilma S. T. Viana4, Sandra G. Pasoto5, Rosa M. Pereira4, Paulo C. Serafin2, Eduardo F. Borba6 and Clovis A. Silva7, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 2Gynecology Department, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 6Rheumatology Division; University of São Paulo, São Paulo, Brazil, 7Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Reduction of ovarian reserve has been observed in childhood-onset SLE (c-SLE) and adult SLE populations, and most of them were limited to follicle stimulating…
  • Abstract Number: 1256 • 2013 ACR/ARHP Annual Meeting

    Depression, Anxiety and Suicidal Thoughts In a Cohort Of Pediatric Lupus and Mixed Connective Tissue Disease Patients

    Andrea Knight1, Pamela F. Weiss2, Knashawn Morales3 and Ron Keren4, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Emerging data reveals that depression and anxiety disorders are highly prevalent in adult patients with systemic lupus erythematosus (SLE). These disorders are associated with…
  • Abstract Number: 1257 • 2013 ACR/ARHP Annual Meeting

    Feasibility and Clinical Implications Of The Pediatric Automated Neuropsychological Assessment Metrics for Screening Of Childhood-Onset Neuropsychiatric Systemic Lupus Erythematosus

    Patricia Vega-Fernandez1, Natasha M. Ruth2, Deborah M. Levy3, Frank Zelko4, Eyal Muscal5, Marisa S. Klein-Gitelman6, HaiMei Liu7, Adam Huber8, Jiha Lee9, Jessica Hummel9, Lori B. Tucker10, Tresa Roebuck-Spencer11 and Hermine Brunner12,13, 1Division of Rheumatology, Cincinanti Children's Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 3Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 4Pediatric Neuropsychology Service, Children's Memorial Hospital, Chicago, IL, 5TCH Pediatric Rheum Center, Baylor College of Medicine, Houston, TX, 6Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, 7Children's Hospital of Fundan University, Shanghai, China, 8IWK Health Centre, Halifax, NS, Canada, 9Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 10Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 11Cognitive Science Research Center, University of Oklahoma, Norman, OK, 12Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 13Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

     Background/Purpose: Neuropsychiatric disease is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Signs of cNPSLE can be subtle and difficult to ascertain in daily clinical practice.…
  • Abstract Number: 1258 • 2013 ACR/ARHP Annual Meeting

    Cognitive Functions In Childhood-Onset Systemic Lupus Erythematosus

    Bruna Bellini1, Cleonice de Souza1, Mariana Postal1, Nailu A. Sinicato1, Paula T Fernandes2, Roberto Marini3 and Simone Appenzeller4, 1Medicine, State University of Campinas, Campinas, Brazil, 2Faculty of Physical Education, State University of Campinas, Campinas, Brazil, 3State University of Campinas, Campinas, Brazil, 4Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil

    Background/Purpose: To determine differences in cognitive functions in childhood-onset systemic lupus erythematosus (cSLE).  Methods: We performed a cross-sectional study including patients with age of onset…
  • Abstract Number: 1259 • 2013 ACR/ARHP Annual Meeting

    Cognitive Dysfunction In Childhood Systemic Lupus Erythematosus: Comparison Of Different Classification Criteria

    Bruna Bellini1, Cleonice de Souza1, Mariana Postal1, Nailu A. Sinicato1, Roberto Marini2, Paula T Fernandes3 and Simone Appenzeller4, 1Medicine, State University of Campinas, Campinas, Brazil, 2State University of Campinas, Campinas, Brazil, 3Faculty of Physical Education, State University of Campinas, Campinas, Brazil, 4Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil

    Background/Purpose: Cognitive deficits are frequently observed in systemic lupus erythematosus (SLE), in both adult and childhood (cSLE) onset. However there are several different cutoff levels…
  • Abstract Number: 1260 • 2013 ACR/ARHP Annual Meeting

    Serum S100β Is Associated With Neuropsychiatric Manifestations In Childhood-Onset Systemic Lupus Erythematosus

    Aline T. Lapa1, Mariana Postal1, Nailu A. Sinicato1, Bruna Bellini1, Paula T Fernandes2, Roberto Marini3 and Simone Appenzeller4, 1Medicine, State University of Campinas, Campinas, Brazil, 2Faculty of Physical Education, State University of Campinas, Campinas, Brazil, 3State University of Campinas, Campinas, Brazil, 4Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil

    Background/Purpose: Involvement of the central nervous system (CNS) in systemic lupus erythematosus (SLE) is an important source of morbidity and mortality.  S100β has been considered…
  • Abstract Number: 1261 • 2013 ACR/ARHP Annual Meeting

    The Usefulness Of Traditional Neurocognitive Testing and N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients

    Natasha M. Ruth1, Mary C. Kral2, Tamara K. Nowling3, Stephanie Slan4, Murray H. Passo5 and Gary S. Gilkeson4, 1Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 2Genetics and Developmental Pediatrics, MUSC, Charleston, SC, 3Medicine/Rheumatology, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, 4Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 5Pediatrics, Medical University of South Carolina, Charleston, SC

    Background/Purpose: In order to identify lupus patients at risk for CNS disease, and specifically, cognitive dysfunction, the ACR recommended a standard battery of tests for…
  • Abstract Number: 1262 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry

    Alexis Boneparth1, Norman T. Ilowite1 and The CARRA Registry Investigators2, 1Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, 2Duke Clinical Research Institute, Durham, NC

    Background/Purpose: Lupus nephritis (LN) affects many patients with pediatric systemic lupus erythematosus (pSLE) and is a significant cause of disease morbidity. Inability to achieve remission…
  • Abstract Number: 1263 • 2013 ACR/ARHP Annual Meeting

    Childhood-Onset Systemic Lupus Erythematosus In Ontario:  Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage

    Deborah M. Levy1, Nadia Gunraj2, Janet E. Pope3, J. Carter Thorne4, Wesley Fidler5, Peter B. Dent6, Johannes Roth7, Roberta A. Berard8, Murray Berall9, Astrid Guttmann10 and Earl D. Silverman11, 1Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, 4Southlake Regional Health Centre, Newmarket, ON, Canada, 5Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, 6McMaster University, Hamilton, ON, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8Children's Hospital of Western Ontario, London, ON, Canada, 9Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, 10Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 11Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative…
  • Abstract Number: 1264 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients

    Julia G. Harris1,2, Kristyn I. Maletta3, Evelyn M. Kuhn3 and Judyann C. Olson1,2, 1Medical College of Wisconsin, Milwaukee, WI, 2Children's Hospital of Wisconsin, Milwaukee, WI, 3National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI

    Background/Purpose:   Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually every organ system and may lead to significant morbidities.  A…
  • « Previous Page
  • 1
  • …
  • 2345
  • 2346
  • 2347
  • 2348
  • 2349
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology